Skeptical on: Business, Tech, Energy, Global issues
BREAKING—analysis of Russian #SARSCoV2 vaccine’s phase 3 trial with ~ 20,000 participants finds that a 2-dose regimen has an efficacy of 91.6% against symptomatic #COVID19. No serious adverse events were deemed to be associated with vaccination. 100% efficacy for severe illness. pic.twitter.com/X8Z6i1yEnJ
— Eric Feigl-Ding (@DrEricDing) February 2, 2021
